How fast red blood cells break down in sickle cell anaemia varies between patients in ways that matter clinically. This variant reached genome-wide significance in a study whose headline finding was elsewhere (NPRL3) — its own nearest genes are olfactory receptors with no established link to blood biology, stated plainly rather than dressed up with an invented mechanism.
Sickle cell anaemia causes red blood cells to break down faster than normal — haemolysis — and how severe that breakdown is varies between patients in ways that matter clinically: it tracks with complications including pulmonary hypertension and leg ulcers. Milton et al. 2013 built a haemolytic severity score from several blood markers, combined using principal component analysis, and ran a genome-wide association study against it across multiple sickle cell cohorts.
The paper's headline, best-explained result is a variant in NPRL3, whose effect is plausibly mediated through regulating HBA1/HBA2 (the alpha globin genes) — a clear, mechanistically grounded finding directly relevant to red blood cell biology.
The variant on this page, rs7948471, reached genome-wide significance in the same body of work (P = 3.0 × 10⁻¹⁰) but sits near OR51I1 and OR51I2, both olfactory receptor genes with no established connection to red blood cell biology. That is stated plainly here rather than dressed up with an invented mechanism: a genome-wide association study's "nearest gene" is sometimes simply the closest gene to a statistically real signal, not evidence that the gene itself does anything relevant to the trait — and olfactory receptor genes turning up this way near real signals elsewhere in the genome is a recognised pattern in genome-wide results generally, not unique to this study.
Haemolysis severity in sickle cell anaemia is monitored through standard blood markers, and complications it tracks with are managed clinically — not through this variant. This page reports a statistically real signal without a settled biological story behind it, which is a meaningfully different, weaker kind of finding than the paper's own NPRL3 result.
The honest reading here is that this position in the genome is statistically associated with haemolysis severity in this study, and the reason why is not established. That gap is reported rather than filled with speculation.
Sickle cell disease and its complications have other variants catalogued separately where the evidence is stronger and the mechanism is clearer, including the NPRL3/HBA1-HBA2 finding from this same study.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Haemolysis Severity in Sickle Cell Anaemia comes down to these specific, well-studied positions — not a diagnosis.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Haemolysis Severity in Sickle Cell Anaemia. MyGeneLog™. https://www.mygenelog.com/conditions/sickle-cell-anemia-haemolysis
It reached genome-wide statistical significance in one study, but the biological reason is not established — its nearest genes are olfactory receptors with no known role in red blood cell biology. This is a weaker, less-understood finding than some other variants on this site.
Because that is honestly what sits nearest to this statistically significant position in the genome, and this page reports that rather than inventing a connection. A GWAS signal's nearest gene is sometimes just proximity, not evidence of relevance — a real and recognised limitation of this kind of study.
A variant in NPRL3, whose effect is plausibly explained through its role regulating HBA1 and HBA2, the alpha globin genes — a mechanistically clear result, unlike the variant on this specific page.
Through standard blood markers tracked clinically over time, and through monitoring for the complications haemolysis severity is linked to, such as pulmonary hypertension. This variant is not part of that clinical monitoring.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.